Omniscient Neurotechnology
Omniscient Neurotechnology (o8t) develops Quicktome, an FDA-cleared, cloud-hosted AI platform that converts MRI data into personalized brain network maps for neurosurgeons and neuroscience researchers at hospitals and academic medical centers globally.
- Company typePrivate
- Founded2019
- HeadquartersSydney, Australia
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Omniscient Neurotechnology does
Omniscient Neurotechnology (o8t) is a Sydney-based medical software company founded in 2019 that develops Quicktome, an FDA-cleared, cloud-hosted (AWS) AI platform for connectomic brain mapping. The product ingests MRI and resting-state functional MRI scans and applies proprietary Constrained Spherical Deconvolution (CSD) tractography algorithms to produce personalized structural and functional brain network maps used in pre-surgical planning and neuroscience research. The platform is SOC 2 Type II certified and protected by a portfolio of 37 USPTO patents, with the underlying science documented across 93 peer-reviewed publications.
The company sells primarily to neurosurgeons and neuroscience researchers at large academic medical centers and specialty hospitals across the US, Australia, and other markets, using an enterprise SaaS go-to-market supported by a global distributor network. Named customers include Mount Sinai, Macquarie University Hospital, University of Miami Hospital, Miami Neuroscience Institute, WVU Medicine, UAMS, and the Jacobs Institute. Reimbursement economics have been substantially de-risked by the establishment of Category III CPT code 1039T, effective July 2026, which creates a formal US payment pathway for AI connectomic brain mapping.
The business is led by CEO Stephen Scheeler (formerly Facebook ANZ), co-founder and CMO Dr. Michael Sughrue (neurosurgeon), co-founder and CTO Dr. Stephane Doyen, COO Rob Malcolm, CFO Adam Fraser, and CCO Todd Smalley. To date, the company has raised approximately $70M+ across Series A through an oversubscribed Series D, with the May 2026 $27.2M round funding US commercial expansion and a new Sydney Connectomics Center of Excellence.
Omniscient Neurotechnology firmographics
Firmographics- Name
- Omniscient Neurotechnology
- Legal name
- Omniscient Neurotechnology
- Website
- https://o8t.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Omniscient Neurotechnology (o8t) develops Quicktome, an FDA-cleared, cloud-hosted AI platform that converts MRI data into personalized brain network maps for neurosurgeons and neuroscience researchers at hospitals and academic medical centers globally.
- Ownership category
- akta.pro rank
Omniscient Neurotechnology industry classification
Industry- Product category
- Neuroimaging Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Omniscient Neurotechnology is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Omniscient Neurotechnology business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- Quicktome SaaS Platform Subscription: Omniscient generates revenue through a software-as-a-service model, providing healthcare institutions with cloud-based access to the Quicktome connectomic analysis platform. The platform supports cranial surgery, neuro-oncology, and stroke applications, with reimbursement established via CPT code 1039T for connectomic analysis in the US healthcare system.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise hospital and research institution licensing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Omniscient Neurotechnology product offering
Product offeringCore offering
Omniscient Neurotechnology develops and sells Quicktome, an FDA-cleared AI-powered connectomic analysis platform that automatically processes MRI and resting-state functional MRI (rs-fMRI) scans to generate personalized brain network maps (connectomes) for neurosurgeons and neuroscience researchers. The cloud-based software supports cranial surgery, neuro-oncology, stroke, and movement disorders planning, with reimbursement established via CPT code 1039T in the US healthcare system.
Product overview
Omniscient Neurotechnology offers the Quicktome platform, an AI-powered connectomic analysis platform. The core product, Quicktome, provides clinicians with detailed insights into patient-specific brain networks by automatically analyzing MRI and rs-fMRI data. The company also offers Quicktome FC (Functional Connectome), an FDA-cleared module that maps functional connectivity. Quicktome serves two primary segments: neurosurgeons who use it for pre-surgical planning, and researchers who use it for neural data analysis. The platform generates personalized brain maps and is deployed at major hospitals and research institutions worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- Quicktome: AI-powered connectomic analysis platform that provides clinicians with detailed insights into patient-specific brain networks and function. Automatically analyzes MRI and resting-state fMRI data with AI-enabled post-processing to support individualized treatment planning.
- Quicktome FC (Functional Connectome)
Products and services
- Quicktome AI-powered connectomic analysis platform that provides clinicians with detailed insights into patient-specific brain networks and function. Automatically analyzes millions of data points derived from MRI and resting-state functional MRI (rs-fMRI) with AI-enabled post-processing to support individualized treatment planning.
- Quicktome FC (Functional Connectome) FDA-cleared AI brain-mapping software that maps functional connectivity of a patient's unique networks, generating individualized neural network templates for surgical planning and functional analysis.
- Quicktome for Neurosurgeons Delivers precise knowledge of a patient's unique brain networks for actionable surgical insights prior to life-changing surgery. Helps neurosurgeons personalize treatment plans rather than relying on generalized anatomical diagrams.
- Quicktome for Researchers Platform that processes vast quantities of neural data to provide invaluable structural and functional information specific to each subject for neuroscience research applications.
Quantifiable outcome
- MRI image processing reduced from hours of manual intervention to under 2 hours with less than 5 minutes of direct surgeon intervention
- +1 more outcomes
Companies that use Omniscient Neurotechnology
Customer profileNamed customers7 records
Segments1 record
Ideal customer profiles2 records
Omniscient Neurotechnology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Omniscient Neurotechnology partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and supporting.
- The Jacobs Institute, Inc.coreStrategic partnership to launch the Connectomics Innovation Program, aiming to integrate connectomics into clinical practice and research. The program focuses on neurological conditions including stroke, coma, and neurologic deficits, leveraging Omniscient's AI-powered Quicktome platform. This partnership represents Omniscient's most significant clinical co-development alliance.
- AWS (Amazon Web Services)coreOmniscient's cloud-based Quicktome platform runs on AWS cloud infrastructure. AWS highlighted the company as a startup case study, with CTO Stephane Doyen featured in AWS startup content and Werner Vogels (VP & CTO of Amazon.com) writing about Omniscient's unique cloud-based technology. The cloud architecture enables scalable processing of MRI data.
- Global Distribution PartnerssupportingOmniscient has several distribution partners globally, listed on the Quicktome Distributors page. These partners cover regions where the company does not have direct sales presence, enabling market reach across multiple geographic territories.
- Human Connectome ProjectsupportingOmniscient's research and brain mapping technology is built upon data from the Human Connectome Project, which provides the foundational neuroimaging datasets used to develop and validate the company's connectomic analysis methods and brain network parcellations.
Scale indicators9 records
Recent moves8 records
Expansion highlights1 record
Omniscient Neurotechnology competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key highlights7 records
Customer concentration
Omniscient Neurotechnology social profiles
Digital presenceOmniscient Neurotechnology compliance and trust
Trust signalCompliance2 records
Omniscient Neurotechnology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Omniscient Neurotechnology leadership team
Management profileNumber of profiles
Profiles6 records
Omniscient Neurotechnology funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Omniscient Neurotechnology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Omniscient Neurotechnology
What does Omniscient Neurotechnology do?
Omniscient Neurotechnology develops and sells Quicktome, an FDA-cleared AI-powered connectomic analysis platform that automatically processes MRI and resting-state functional MRI (rs-fMRI) scans to generate personalized brain network maps (connectomes) for neurosurgeons and neuroscience researchers. The cloud-based software supports cranial surgery, neuro-oncology, stroke, and movement disorders planning, with reimbursement established via CPT code 1039T in the US healthcare system.
Is Omniscient Neurotechnology a public or private company?
Omniscient Neurotechnology is a private company. It is classified as venture growth investor backed and is currently operating.
When was Omniscient Neurotechnology founded?
Omniscient Neurotechnology was founded in 2019. It employs 51 to 100 people.
Where is Omniscient Neurotechnology based?
Omniscient Neurotechnology is headquartered in Sydney, Australia, in the Oceania region.
How does Omniscient Neurotechnology make money?
One revenue line is on record: quicktome SaaS Platform Subscription.
Does Omniscient Neurotechnology have an API?
No public API is recorded for Omniscient Neurotechnology.
What industry is Omniscient Neurotechnology in?
Omniscient Neurotechnology's product category is Neuroimaging Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 541714 and its SIC code is 3841.